An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...
Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...
A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...
The next breakthrough in cancer screening is emerging from the convergence of artificial intelligence and canine biology. That’s the thesis behind SpotitEarly, a startup that recently launched in the ...
The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results